INmune Bio (INMB)
Develops innate-immunity therapies for rare disease, Alzheimer’s disease and cancer.
$2.43
Pre-market+0.07 (+2.97%)
At close$2.36(+5.36%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions86 holders · as of Mar 31, 2026 | 19.37% | 5.38M shares | |
| Insiders4 holders · as of Jul 7, 2026 | 16.05% | 4.45M shares | |
| Strategic holders1 holder · as of Aug 14, 2025 | 5.24% | 1.45M shares | |
| Otherremainder | 59.34% | 16.47M shares |
27.75M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
86 holders · 5.38M shares · 18 new positions · 43 increased · 22 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 1.19M | 4.30% | −18.0K | May 13, 2026 |
| Vanguard Capital Management LLC | 687.0K | 2.48% | +687.0Knew | May 15, 2026 |
| Geode Capital Management, LLC | 495.0K | 1.78% | +53.3K | May 15, 2026 |
| State Street Corp | 290.9K | 1.05% | −56.4K | May 15, 2026 |
| AQR Capital Management LLC | 270.3K | 0.97% | +249.8K | May 15, 2026 |
| UBS Group AG | 253.3K | 0.91% | +192.5K | May 5, 2026 |
| Goldman Sachs Group Inc | 231.6K | 0.83% | +175.1K | May 15, 2026 |
| Raymond James Financial Inc | 203.2K | 0.73% | −7.4K | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 5.20% | 1.45M | 13G | Aug 14, 2025 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.